Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Patient-Reported Outcomes of Patients With Advanced Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab Versus Sunitinib (CheckMate 214): A Randomised, Phase 3 TrialLancet Oncol 2019 Jan 15;[EPub Ahead of Print], D Cella, V Grünwald, B Escudier, HJ Hammers, S George, P Nathan, MO Grimm, BI Rini, J Doan, C Ivanescu, J Paty, S Mekan, RJ Motzer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.